CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,791,880 | +220.3% | 262,000 | +94.1% | 4.06% | +120.7% |
| Q2 2023 | $2,432,700 | +51.5% | 135,000 | +35.0% | 1.84% | +106.6% |
| Q1 2023 | $1,606,000 | -64.1% | 100,000 | -51.0% | 0.89% | -40.6% |
| Q1 2022 | $4,478,000 | -52.4% | 204,000 | -38.4% | 1.50% | -42.2% |
| Q4 2021 | $9,404,000 | +131.5% | 331,000 | +71.5% | 2.59% | +143.2% |
| Q3 2021 | $4,063,000 | -59.6% | 193,000 | -63.8% | 1.07% | -54.3% |
| Q2 2021 | $10,048,000 | +81.7% | 533,033 | +47.3% | 2.33% | +51.9% |
| Q1 2021 | $5,530,000 | +8.3% | 361,930 | 0.0% | 1.54% | -19.5% |
| Q4 2020 | $5,107,000 | – | 361,930 | – | 1.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |